Search research articles
Contact Us
Filters
Showing results (11-20 of 56) with videos related to
Page
of 6
Sort By:
Current Medicinal Chemistry
|
August 21, 2007
Nanochemistry-based immunotherapy for HIV-1
F Lori, S A Calarota, J Lisziewicz
Journal of Virology
|
December 1, 1990
CD4-independent infection by human immunodeficiency virus type 1 after phenotypic mixing with human T-cell leukemia viruses
P Lusso, F Lori, R C Gallo
Current Pharmaceutical Design
|
December 8, 2004
"Virostatics" as a potential new class of HIV drugs
L M Kelly, J Lisziewicz, F Lori
British Journal of Pharmacology
|
September 24, 2010
Strategies to improve efficacy and safety of a novel class of antiviral hyper-activation-limiting therapeutic agents: the VS411 model in [corrected] HIV/AIDS
D De Forni, M R Stevens, F Lori
The Journal of Infectious Diseases
|
October 23, 1997
Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy
A De Antoni, A Foli, J Lisziewicz, et al.
Journal of Magnetic Resonance (San Diego, Calif. : 1997)
|
December 4, 2003
Definition of displacement probability and diffusion time in q-space magnetic resonance measurements that use finite-duration diffusion-encoding gradients
Nicolas F Lori, Thomas E Conturo, Denis Le Bihan
The Journal of Biological Chemistry
|
March 8, 1996
HIV-1 protein expression from synthetic circles of DNA mimicking the extrachromosomal forms of viral DNA
A Cara, A Cereseto, F Lori, et al.
Current Medicinal Chemistry
|
February 3, 2007
Virostatics: a new class of anti-HIV drugs
F Lori, A Foli, L M Kelly, et al.
Journal of Molecular Biology
|
February 27, 1999
Analysis of amino insertion mutations in the fingers subdomain of HIV-1 reverse transcriptase
P L Boyer, J Lisziewicz, F Lori, et al.
Journal of Biological Regulators and Homeostatic Agents
|
May 11, 2002
Role of hydroxyurea during structured treatment interruptions
A Foli, E Seminari, E Ravot, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 56) with videos related to
Sort By:
Page
of 6
Current Medicinal Chemistry
|
August 21, 2007
Nanochemistry-based immunotherapy for HIV-1
F Lori, S A Calarota, J Lisziewicz
Journal of Virology
|
December 1, 1990
CD4-independent infection by human immunodeficiency virus type 1 after phenotypic mixing with human T-cell leukemia viruses
P Lusso, F Lori, R C Gallo
Current Pharmaceutical Design
|
December 8, 2004
"Virostatics" as a potential new class of HIV drugs
L M Kelly, J Lisziewicz, F Lori
British Journal of Pharmacology
|
September 24, 2010
Strategies to improve efficacy and safety of a novel class of antiviral hyper-activation-limiting therapeutic agents: the VS411 model in [corrected] HIV/AIDS
D De Forni, M R Stevens, F Lori
The Journal of Infectious Diseases
|
October 23, 1997
Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy
A De Antoni, A Foli, J Lisziewicz, et al.
Journal of Magnetic Resonance (San Diego, Calif. : 1997)
|
December 4, 2003
Definition of displacement probability and diffusion time in q-space magnetic resonance measurements that use finite-duration diffusion-encoding gradients
Nicolas F Lori, Thomas E Conturo, Denis Le Bihan
The Journal of Biological Chemistry
|
March 8, 1996
HIV-1 protein expression from synthetic circles of DNA mimicking the extrachromosomal forms of viral DNA
A Cara, A Cereseto, F Lori, et al.
Current Medicinal Chemistry
|
February 3, 2007
Virostatics: a new class of anti-HIV drugs
F Lori, A Foli, L M Kelly, et al.
Journal of Molecular Biology
|
February 27, 1999
Analysis of amino insertion mutations in the fingers subdomain of HIV-1 reverse transcriptase
P L Boyer, J Lisziewicz, F Lori, et al.
Journal of Biological Regulators and Homeostatic Agents
|
May 11, 2002
Role of hydroxyurea during structured treatment interruptions
A Foli, E Seminari, E Ravot, et al.
Page
of 6